Company profile
Coherus Oncology, Inc.
NASDAQ: CHRS · Healthcare · Biotechnology
#457 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
61CFH 65DQ 72GM 29SS 63
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$46.9M
Rev growth YoY (TTM)
-76.3%
Net income (FY)
$168.0M
Employees
147
as of 2026-08-14
Market cap
$176.1M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$42.2M$42.2M2025
Net income$168.0M$168.0M2025
Operating income-$181.1M-$181.1M2025
Total assets$258.3M$258.3M2025
Liabilities$197.3M$197.3M2025
Equity$61.0M$61.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product and Service, Other100%
By geography
Not disclosed.
The read
What is Coherus Oncology, Inc.’s revenue?
Coherus Oncology, Inc. booked $42.2M in FY2025 revenue, contracting 84% year over year — slower than 89% of Healthcare companies we track, at a 398.4% net margin.
Peers · Healthcare
Wave Life Sciences Ltd.63CRubicon Organics Inc.63CSS Innovations International, Inc.53DBiofrontera Inc.46DSelectis Health, Inc.60CKORU Medical Systems, Inc.72BNeighbors
San Mateo →Key facts
CEODennis Lanfear
SectorHealthcare
IndustryBiotechnology
HeadquartersRedwood City, CA
ExchangeNASDAQ: CHRS
Employees147
IPO date2014-11-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.